



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 292 312 B1**

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
28.04.2004 Bulletin 2004/18

(51) Int Cl.7: **A61K 31/70, A23L 1/305,
A23L 1/09, A23L 1/236,
A23L 1/302**

(21) Application number: **01941001.8**

(86) International application number:
PCT/IT2001/000283

(22) Date of filing: **01.06.2001**

(87) International publication number:
WO 2001/095915 (20.12.2001 Gazette 2001/51)

(54) **DIETARY SUPPLEMENT ENHANCING THE MUSCULAR ENERGY METABOLISM, COMPRISING
AN ALKANOYL CARNITINE AND RIBOSE**

**NAHRUNGSERGÄNZUNG ZUR VERBESSERUNG DES MUSKELENERGIESTOFFWECHSELS,
ENTHALTEND ALKANOYL-CARNITINE UND RIBOSE**

**SUPPLEMENT ALIMENTAIRE RENFORCANT LE METABOLISME DE LA TONICITE MUSCULAIRE,
A BASE DE CARNITINE D'ALCANOYLE ET DE RIBOSE**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(72) Inventor: **POLA, Pietro
I-00040 Rocca di Papa (IT)**

(30) Priority: **14.06.2000 IT RM000323**

(74) Representative: **Cavattoni, Fabio et al
Cavattoni & Raimondi
Viale dei Parioli, 160
00197 Roma (IT)**

(43) Date of publication of application:
19.03.2003 Bulletin 2003/12

(73) Proprietor: **SIGMA-TAU Industrie
Farmaceutiche Riunite S.p.A.
00144 Roma (IT)**

(56) References cited:
**EP-A- 0 652 012 WO-A-88/01861
WO-A-94/15488 WO-A-99/65476**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention relates to a health food/dietary supplement comprising as its characterising ingredients an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine and propionyl L-carnitine or their pharmacologically acceptable salts or mixtures of the same and a monosaccharide pentose, particularly ribose or its phosphorylated analogues.

[0002] It has been found that the above-mentioned composition is extremely effective in exerting a potent stimulation of muscular energy metabolism, and can thus be profitably used in the prevention of myocardial insufficiency and in post-infarct conditions, as well as in the course of prolonged muscular effort during physical and sporting exercises, owing to the unexpected synergistic effect exerted by its components.

[0003] Compositions comprising a sugar, such as D(-)ribose, and acetyl-L-carnitine for the manufacture of a medicament for the treatment of Alzheimer disease are disclosed in EP-A-0 652 012.

[0004] Isovaleryl L-carnitine, a natural component of the pool of carnitines, presents specific activity at lysosomal level and on the cytosolic movements of calcium. It is therefore capable of intervening in proteolytic processes such as occur during intense, prolonged effort and of protecting a number of organs, such as the liver, against the action of toxic substances.

[0005] Propionyl L-carnitine exerts an intense antioxidant effect and is particularly elective in enhancing the peripheral circulation and cardiac functional capacity.

[0006] Moreover, muscular carnitine transferase possesses a greater affinity for propionyl L-carnitine than for L-carnitine, and consequently propionyl L-carnitine possesses a higher degree of specificity for cardiac and skeletal muscle. In addition, propionyl L-carnitine transferase, transporting the propionyl group, increases the uptake of this component by the muscle cells, which may be of particular importance for energy purposes, in that the propionate can be used by the mitochondria as an anapleurotic substrate and provide energy in the absence of oxygen.

[0007] Equally well known are the metabolic effects of ribose. Ribose is a monosaccharide pentose which is important in the body for the synthesis of nucleotides and other metabolic products. It is formed by conversion of glucose via the pentose phosphates. In the presence of a ribokinase ribose is phosphorylated to ribose-5-phosphate which, through the production of 5-phosphoribosyl-1-pyrophosphate (PRPP), can be used for the synthesis of nucleotides necessary for the production of ATP. PRPP, in addition to intervening in the production of ATP, is also important for the synthesis of nucleotides such as adenine and hypoxanthine and of ribonucleotides and deoxyribonucleotides.

[0008] It has now been found surprisingly that a composition comprising a combination of the following as its characterising components:

(a) an alkanoyl L-carnitine selected from the group comprising isovaleryl L-carnitine, propionyl L-carnitine or their pharmacologically acceptable salts or mixtures of the same; and

(b) ribose or a phosphorylate derivative thereof,

constitutes an effective health food/dietary supplement for the prevention of states of myocardial or skeletal muscle dysfunction related to conditions of anoxia or insufficient energy supply as occurring in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue, owing to the potent and unexpected synergistic effect exerted by its components.

[0009] The dietary supplement according to the present invention may additionally contain

(c) a "carnitine" selected from the group comprising L-carnitine, acetyl L-carnitine, butyryl L-carnitine and valeryl L-carnitine, or their pharmacologically acceptable salts or mixtures of the same.

[0010] The weight-to-weight ratios of the above-mentioned components (a):(b):(c) range from 1:1:1 to 1:10:2.

[0011] The surprising synergistic effect achieved with the combination of "carnitines" (term denoting collectively both L-carnitine and the alkanoyl L-carnitines), particularly isovaleryl L-carnitine and/or propionyl L-carnitine, and ribose, has been demonstrated by several pharmacological tests (some of which are described here below) chosen in such a way as to prove strongly predictive for the purposes of the practical use of this composition in the preventive/nutritional/dietetic field.

[0012] In particular, this unexpected synergistic effect on the increase in energy capabilities at both cardiac and muscular level exerted by the combination according to the present invention enables it to be used for the manufacture of a medicament for the prevention of both myocardial insufficiency and of muscle fatigue such as occur in cases of myocardial ischaemia or in the course of intense muscular effort due to prolonged physical exercise or sporting activity.

Test of ATP concentrations in heart subjected to anoxia

[0013] In this test the technique adopted was the one using papillary muscle of rabbit heart perfused and subjected to anoxia which, as is known, leads to an impoverishment of its ATP energy reserves. With this test, the aim was to observe whether or not preventive treatment with isovaleryl L-carnitine, with propionyl L-carnitine, with a carnitine combination or with ribose, or with a combination of these was capable of protecting cardiac muscle against the loss of ATP induced by anoxia.

[0014] In this test, a batch of New Zealand rabbits was used, subdivided into different groups which were injected intravenously every day for three consecutive days with isovaleryl L-carnitine alone (100 mg/kg), propionyl L-carnitine alone (100 mg/kg) or a carnitine combination consisting of propionyl L-carnitine (25 mg/kg), acetyl L-carnitine (25 mg/kg), L-carnitine (25 mg/kg), and isovaleryl L-carnitine (25 mg/kg) or with ribose alone (100 mg/kg), or ribose combined with the above-mentioned "carnitines".

[0015] At the end of the third day of treatment, all the animals were sacrificed and their hearts excised. Sections of papillary muscle measuring 1 mm in diameter and 4-5 mm in thickness were isolated from the excised hearts. The isolated papillary muscle was perfused in a thermostatic bath with a saturated 100% O₂ solution.

[0016] The anoxic state was obtained by introducing 100% N₂ instead of O₂ into the bath. For the measurement of the ATP concentrations in the papillary muscle the method described by Strehler was adopted (Strehler B.L. Methods in Enzymology 111 N.Y. Acad. Press., 879, 1957).

[0017] The analysis was carried out on tissue samples maintained in conditions of perfusion with oxygen for 90 minutes and after a period of anoxia of the same duration.

[0018] The results of this test, presented in Table 1, indicate that propionyl L-carnitine, isovaleryl L-carnitine, the carnitine combination and ribose are individually capable of partly protecting the ATP present in papillary muscle against anoxia, but that it was only with the combination of propionyl L-carnitine or isovaleryl L-carnitine plus ribose or with the combination of the carnitine combination plus ribose that complete protection against the anoxia-induced reduction in ATP could be obtained, thus demonstrating the potent synergistic effect exerted by the components of the combination.

Table 1

Test of ATP concentrations in papillary muscle of heart subjected to hypoxia		
Treatment	ATP concentration (mol/g tissue)	
	Before hypoxia	After hypoxia
Controls	1.60±0.55	0.41±0.055
Isovaleryl L-carnitine	1.50±0.60	0.55±0.65
Propionyl L-carnitine	1.64±0.79	0.60±0.040
Carnitine combination	1.55±0.50	0.62±0.060
Ribose	1.62±0.39	0.55±0.075
Isovaleryl L-carnitine + ribose	1.50±0.25	1.15±0.055
Propionyl L-carnitine + ribose	1.61±0.45	1.25±0.35
Carnitine combination + ribose	1.65±0.60	1.16±0.30

Experimental myocardial anoxia test

[0019] Adopting the technique described by Selych (Selych et al., Angiology, 11, 398, 1960) and modified by Clark (Clark C., J. Pharmacol. Methods, 3, 357, 1980), these tests were used to evaluate the protective activity of isovaleryl L-carnitine, propionyl L-carnitine, carnitine combination, ribose and various combinations of the same against ventricular arrhythmias induced by left coronary ligation in the rat.

[0020] Coronary occlusion and the resulting myocardial anoxia lead, after 5-8 minutes, to the onset of arrhythmias. In these tests, ventricular ectopic contractions were counted for a period of 30 minutes after ligation both in control rats and in rats that had received slow injections into the left ventricle, 15 minutes before ligation, of a solution containing isovaleryl L-carnitine alone (100 mg/kg), propionyl L-carnitine alone (100 mg/kg), or carnitine combination alone consisting of propionyl L-carnitine (25 mg/kg), acetyl L-carnitine (25 mg/kg) and isovaleryl L-carnitine (25 mg/kg) or ribose alone (100 mg/kg), or a combination of ribose plus isovaleryl L-carnitine or propionyl L-carnitine or a combination of ribose plus carnitine combination at the doses described above.

[0021] The results of this test (Table 2) indicate that, whereas isovaleryl L-carnitine alone or propionyl L-carnitine alone or carnitine combination alone or ribose alone produce only slight reductions in the number of ectopic contractions compared to controls, such contractions are reduced almost to the extent of disappearing altogether when ribose is

injected in combination with isovaleryl L-carnitine, or propionyl L-carnitine, or carnitine combination, thus demonstrating the potent and unexpected synergistic effect exerted by the combination according to the present invention.

Table 2

Test of arrhythmia induced by myocardial anoxia		
Treatment	Start of arrhythmias after (min)	No. of ectopic contractions during 30 minutes after ligation
Controls	5 - 7	989±96
Isovaleryl L-carnitine	5 - 7	860±75
Propionyl L-carnitine	5 - 8	830±86
Carnitine combination	5 - 8	810±99
Ribose	5 - 7	855±110
Isovaleryl L-carnitine + ribose	6-7	270±95
Propionyl L-carnitine + ribose	6-8	230±112
Carnitine combination + ribose	6 - 8	207±93

[0022] Some examples of compositions according to the present invention are given hereinbelow:

Lozenges, capsules, tablets

[0023]

1)	Propionyl L-carnitine	500 mg
	Ribose	500 mg
2)	Isovaleryl L-carnitine	500 mg
	Ribose	500 mg
3)	Propionyl L-carnitine	125 mg
	Acetyl L-carnitine	125 mg
	L-carnitine	125 mg
	Isovaleryl L-carnitine	125 mg
	Ribose	500 mg

Granulates or vials

[0024]

4)	Propionyl L-carnitine	1 g
	Ribose	1 g
5)	Isovaleryl L-carnitine	1 g
	Ribose	1 g
6)	Propionyl L-carnitine	1 g
	Ribose	2,5 g

EP 1 292 312 B1

(continued)

7)	Propionyl L-carnitine	250 mg
	Acetyl L-carnitine	250 mg
	Isovaleryl L-carnitine	250 mg
	L-carnitine	250 mg
	Ribose	2,5 g
8)	Propionyl L-carnitine	250 mg
	Acetyl L-carnitine	250 mg
	Isovaleryl L-carnitine	250 mg
	L-carnitine	250 mg
	Ribose	2 g
	Ribonucleic acid	100 mg
	Deoxyribonucleic acid	100 mg
9)	Propionyl L-carnitine	250 mg
	Acetyl L-carnitine	250 mg
	Isovaleryl L-carnitine	250 mg
	L-carnitine	250 mg
	Ribose	2 g
	L-glutamine	100 mg
	L-alanine	100 mg
	L-arginine	100 mg
	L-glicine	100 mg
	L-histidine	100 mg
	L-isoleucine	100 mg
	L-phenylalanine	50 mg
	L-threonine	50 mg
	L-serine	100 mg
10)	Propionyl L-carnitine	250 mg
	Acetyl L-carnitine	250 mg
	Isovaleryl L-carnitine	250 mg
	L-carnitine	250 mg
	Ribose	1 g
	Destrose	0,5 g
	Fructose	0,5 g
	Maltose	0,5 g

EP 1 292 312 B1

(continued)

11)	Propionyl L-carnitine	250 mg
	Acetyl L-carnitine	250 mg
	Isovaleryl L-carnitine	250 mg
	L-carnitine	250 mg
	Ribose	1 g
	Glucose-1,6-diphosphate	200 mg
	Fructose-1,6-diphosphate	200 mg
	Galactose-1,6-phosphate	200 mg
	Glycerol-3-phosphate	200 mg
	Phosphenylpyruvate	100 mg
	Thiamine pyrophosphate	5 mg
	Pyridoxal-5-phosphate	5 mg
	Magnesium stearate	2 mg
12)	Propionyl L-carnitine	250 mg
	Acetyl L-carnitine	250 mg
	Isovaleryl L-carnitine	250 mg
	L-carnitine	250 mg
	Ribose	1 g
	Vit. A	1250 U.I.
	Vit. B ₁	0,5 mg
	Vit. B ₆	30 mg
	Vit. C	50 mg
	Vit. E	5 mg
	Nicotinamide	25 mg
	Vit. B ₁₂	100 mcg
	Vit. D	100 U.I.
	Pantothenic acid	30 mg
	Magnesium glycinate	5 mg
	Manganese	1 mg
	L-Selenomethionine	50 mcg
	Molybdenum	10 mcg
	Zinc	1 mg

[0025] What is meant by a pharmacologically acceptable salt of the various carnitines mentioned in the present invention, is, in addition to the respective inner salts, any salt of these with an acid which does not give rise to unwanted toxic or side effects. These acids are well known to pharmacologists and to experts in pharmaceutical technology.

[0026] Examples of such salts are the following: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; mucate; orotate; oxalate, acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphonate.

[0027] Among these salts, isovaleryl L-carnitine acid fumarate (US 5,227,518) is particularly preferred.

[0028] A list of FDA-approved pharmacologically acceptable acids is given in Int. J. Pharm., 33, 1986, 201-217.

[0029] The supplement of the invention may further comprise vitamins, coenzymes, mineral substances, aminoacids and antioxidants. The supplement may be manufactured in solid, semi-solid or liquid form or in the form of tablets, lozenges, capsules, pills, granulates, syrups, vials or drops.

Claims

1. A food/dietary supplement which comprises the following characterizing ingredients:

- (a) an alkanoyl L-carnitine selected from the group comprising isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and
(b) ribose or a phosphorylate derivative thereof.

2. The supplement of claim 1, further comprising:

- (c) a "carnitine" selected from the group comprising L-carnitine, acetyl L-carnitine, butyryl L-carnitine and valeryl L-carnitine or the pharmacologically acceptable salts or mixtures thereof.

3. The supplement of anyone of the preceding claims which further comprises vitamins, sugars, coenzymes, mineral substances, aminoacids, peptides and antioxidants.

4. The supplement of any of the preceding claims wherein the pharmacologically acceptable salt is selected from the group comprising: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphate.

5. The supplement of any of the preceding claims, for the prevention of myocardial insufficiency and in post-infarct conditions, psychomotor alterations and to cope with the increased muscular energy requirements.

6. A food/dietary supplement of any of the preceding claims in solid, semi-solid or liquid form.

7. The food/dietary supplement of any of the preceding claims in the form of tablets, capsules, lozenges, pills, granulates, creams, syrups or drops.

8. The supplement of any of the preceding claims, wherein the weight ratio of ingredients (a):(b):(c) ranges from 1:1:1 to 1:10:2.

9. The supplement of claim 8, in unit dosage form, comprising:

Propionyl L-carnitine	125 mg
Acetyl L-carnitine	125 mg
L-carnitine	125 mg
Isovaleryl L-carnitine	125 mg
Ribose	500 mg

10. The supplement of claim 8, in unit dosage form, comprising:

Propionyl L-carnitine	250 mg
Acetyl L-carnitine	250 mg
Isovaleryl L-carnitine	250 mg
L-carnitine	250 mg
Ribose	2 g
Ribonucleic acid	100 mg
Deoxyribonucleic acid	100 mg

EP 1 292 312 B1

11. The supplement of claim 8, in unit dosage form, comprising:

Propionyl L-carnitine	250 mg
Acetyl L-carnitine	250 mg
Isovaleryl L-carnitine	250 mg
L-carnitine	250 mg
Ribose	2 g
L-glutamine	100 mg
L-alanine	100 mg
L-arginine	100 mg
L-glicine	100 mg
L-histidine	100 mg
L-isoleucine	100 mg
L-phenylalanine	50 mg
L-threonine	50 mg
L-serine	100 mg

12. The supplement of claim 8, in unit dosage form, comprising:

Propionyl L-carnitine	250 mg
Acetyl L-carnitine	250 mg
Isovaleryl L-carnitine	250 mg
L-carnitine	250 mg
Ribose	1 g
Glucose-1,6-diphosphate	200 mg
Fructose-1,6-diphosphate	200 mg
Galactose-1,6-phosphate	200 mg
Glycerol-3-phosphate	200 mg
Phosphenylpyruvate	100 mg
Thiamine pyrophosphate	5 mg
Pyridoxal-5-phosphate	5 mg
Magnesium stearate	2 mg

13. The supplement of claim 8, in unit dosage form, comprising:

Propionyl L-carnitine	250 mg
Acetyl L-carnitine	250 mg
Isovaleryl L-carnitine	250 mg
L-carnitine	250 mg
Ribose	1 g
Vit. A	1250 U.I.
Vit. B ₁	0,5 mg
Vit. B ₆	30 mg
Vit. C	50 mg
Vit. E	5 mg
Nicotinamide	25 mg
Vit. B ₁₂	100 mcg
Vit. D	100 U.I.
Pantothenic acid	30 mg
Magnesium glycinate	5 mg
Manganese	1 mg
L-Selenomethionine	50 mcg

(continued)

Molybdenum	10 mcg
Zinc	1 mg

14. Use of a combination composition comprising the following ingredients:

- (a) an alkanoyl L-carnitine selected from the group comprising isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and
 (b) ribose or a phosphorylate derivative thereof.

for the manufacture of a medicament for the prevention and/or treatment of states of myocardial or skeletal muscle dysfunction related to conditions of anoxia or insufficient energy supply as occurring in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue.

Patentansprüche

1. Nahrungs/Diätenergänzung, welche die folgenden kennzeichnenden Bestandteile umfasst:

(a) ein Alkanoyl-L-carnitin, ausgewählt aus der Gruppe, umfassend Isovaleryl-L-carnitin, Propionyl-L-carnitin und pharmakologisch zulässige Salze davon oder Mischungen davon, und

(b) Ribose oder ein phosphoryliertes Derivat davon.

2. Ergänzung gemäß Anspruch 1, ferner umfassend:

(c) ein "Carnitin", ausgewählt aus der Gruppe, umfassend L-Carnitin, Acetyl-L-carnitin, Butyryl-L-carnitin und Valeryl-L-carnitin oder pharmakologisch zulässige Salze der Mischungen davon.

3. Ergänzung gemäß einem der vorhergehenden Ansprüche, welche ferner Vitamine, Zucker, Coenzyme, Mineralsubstanzen, Aminosäuren, Peptide und Antioxidanzien umfasst.

4. Ergänzung gemäß einem der vorhergehenden Ansprüche, worin das pharmakologisch zulässige Salz aus der Gruppe ausgewählt ist, umfassend: Chlorid, Bromid, Jodid, Aspartat, saures Aspartat, Zitrat, saures Zitrat, Tartrat, Phosphat, saures Phosphat, Fumarat, saures Fumarat, Glycerophosphat, Glucosephosphat, Lactat, Maleat, saures Maleat, Mucat, Orat, Oxalat, saures Oxalat, Sulfat, saures Sulfat, Trichloracetat, Trifluoracetat und Methansulfonat.

5. Ergänzung gemäß einem der vorhergehenden Ansprüche zur Vorbeugung einer Herzmuskelschwäche und bei Post-Infarktbedingungen, psychomotorischen Veränderungen und zur Erfüllung eines erhöhten muskulären Energiebedarfs.

6. Nahrungs/Diätenergänzung gemäß einem der vorhergehenden Ansprüche in fester, halb-fester oder flüssiger Form.

7. Nahrungs/Diätenergänzung gemäß einem der vorhergehenden Ansprüche in Form von Tabletten, Kapseln, Pastillen, Pillen, Granulaten, Cremeprodukten, Sirupprodukten oder von Tropfen.

8. Ergänzung gemäß einem der vorhergehenden Ansprüche, worin das Gewichtsverhältnis der Bestandteile (a):(b):(c) 1:1:1 bis 1:10:2 beträgt.

9. Ergänzung gemäß Anspruch 8 in Einheitsdosierungsform, umfassend:

Propionyl-L-carnitin	125 mg
Acetyl-L-carnitin	125 mg
L-Carnitin	125 mg

EP 1 292 312 B1

(fortgesetzt)

Isovaleryl-L-carnitin	125 mg
Ribose	500 mg

10. Ergänzung gemäß Anspruch 8 in Einheitsdosierungsform, umfassend:

Propionyl-L-carnitin	250 mg
Acetyl-L-carnitin	250 mg
L-Carnitin	250 mg
Isovaleryl-L-carnitin	250 mg
Ribose	2 g
Ribonucleinsäure	100 mg
Deoxyribonucleinsäure	100 mg

11. Ergänzung gemäß Anspruch 8 in Einheitsdosierungsform, umfassend:

Propionyl-L-carnitin	250 mg
Acetyl-L-carnitin	250 mg
L-Carnitin	250 mg
Isovaleryl-L-carnitin	250 mg
Ribose	2 g
L-Glutamin	100 mg
L-Alanin	100 mg
L-Arginin	100 mg
L-Glicin	100 mg
L-Histidin	100 mg
L-Isoleucin	100 mg
L-Phenylalanin	50 mg
L-Threonin	50 mg
L-Serin	100 mg

12. Ergänzung gemäß Anspruch 8 in Einheitsdosierungsform, umfassend:

Propionyl-L-carnitin	250 mg
Acetyl-L-carnitin	250 mg
L-Carnitin	250 mg
Isovaleryl-L-carnitin	250 mg
Ribose	1 g
Glucose-1,6-diphosphat	200 mg
Fructose-1,6-diphosphat	200 mg
Galactose-1,6-phosphat	200 mg
Glyceryl-3-phosphat	200 mg

EP 1 292 312 B1

(fortgesetzt)

Phosphorylpyruvat	100 mg
Thiaminpyrophosphat	5 mg
Pyridoxal-5-phosphat	5 mg
Magnesiumstearat	2 mg

13. Ergänzung gemäß Anspruch 8 in Einheitsdosierungsform, umfassend:

Propionyl-L-carnitin	250 mg
Acetyl-L-carnitin	250 mg
L-Carnitin	250 mg
Isovaleryl-L-carnitin	250 mg
Ribose	1 g
Vit. A	1250 I.E.
Vit. B ₁	0,5 mg
Vit. B ₆	30 mg
Vit. C	50 mg
Vit. E	5 mg
Nicotinamid	25 mg
Vit. B ₁₂	100 mcg
Vit. D	100 I.E.
Pantothensäure	30 mg
Magnesiumglycinat	5 mg
Mangan	1 mg
L-Selenomethionin	50 mcg
Molybdän	10 mcg
Zink	1 mg

14. Verwendung einer Kombinationszusammensetzung, umfassend die folgenden Bestandteile:

(a) ein Alkanoyl-L-carnitin, ausgewählt aus der Gruppe, umfassend Isovaleryl-L-carnitin, Propionyl-L-carnitin oder die pharmakologisch zulässigen Salze davon oder Mischungen davon, und

(b) Ribose oder ein phosphoryliertes Derivat davon,

zur Herstellung eines Medikaments zur Vorbeugung und/oder Behandlung von Zuständen einer Herz- oder Skelettmuskel-Disfunktion im Zusammenhang mit Bedingungen von Anoxie oder ungenügendem Energienachschub wie bei Koronar- oder Post-Infarktstörungen oder während verlängerter körperlicher Betätigung und Muskelermüdung.

Revendications

1. Complément alimentaire/diététique, qui comprend les ingrédients caractéristiques suivants :

(a) une L-carnitine alcanoylée choisie parmi le groupe comprenant l'isovaléryl-L-carnitine, la propionyl-L-carnitine ou leurs sels pharmacologiquement acceptables ou des mélanges de ceux-ci ; et

(b) du ribose ou un de ses dérivés phosphorylés.

2. Complément selon la revendication 1, comprenant en outre :

(c) une carnitine choisie parmi le groupe comprenant la L-carnitine, l'acétyl-L-carnitine, la butyryl-L-carnitine et la valéryl-L-carnitine, ou leurs sels pharmacologiquement acceptables ou des mélanges de ceux-ci.

3. Complément selon l'une quelconque des revendications précédentes qui comprend en outre des vitamines, des sucres, des coenzymes, des substances minérales, des acides aminés, des peptides et des antioxydants.

4. Complément selon l'une quelconque des revendications précédentes, dans laquelle le sel pharmacologiquement acceptable est choisi parmi le groupe comprenant : le chlorure ; le bromure ; l'iodure ; l'aspartate, l'aspartate acide ; le citrate, le citrate acide ; le tartrate ; le phosphate, le phosphate acide ; le fumarate, le fumarate acide ; le glycérophosphate ; le phosphate de glucose ; le lactate ; le maléate, le maléate acide ; le mucate ; l'orotate ; l'oxalate ; l'oxalate acide ; le sulfate, le sulfate acide ; le trichloroacétate ; le trifluoroacétate et le sulfonate de méthane.

5. Complément selon l'une quelconque des revendications précédentes, pour la prévention de l'insuffisance myocardique et des états post-infarctus, des altérations psychomotrices, et pour faire face aux besoins accrus d'énergie musculaire.

6. Complément alimentaire/diététique selon l'une quelconque des revendications précédentes sous forme solide, semi-solide ou liquide.

7. Complément alimentaire/diététique selon l'une quelconque des revendications précédentes sous forme de comprimés, de gélules, de pastilles, de pilules, de crèmes, de sirops ou de gouttes.

8. Complément selon l'une quelconque des revendications précédentes, dans laquelle le rapport massique des ingrédients (a):(b):(c) varie de 1:1:1 à 1:10:2.

9. Complément selon la revendication 8, sous forme de dose unitaire, comprenant :

Propionyl-L-carnitine	125 mg
Acétyl-L-carnitine	125 mg
L-carnitine	125 mg
Isovaléryl-L-carnitine	125 mg
Ribose	500 mg

10. Complément selon la revendication 8, sous forme de dose unitaire, comprenant :

Propionyl-L-carnitine	250 mg
Acétyl-L-carnitine	250 mg
Isovaléryl-L-carnitine	250 mg
L-carnitine	250 mg
Ribose	2 g
Acide ribonucléique	100 mg
Acide désoxyribonucléique	100 mg

11. Complément selon la revendication 8, sous forme de dose unitaire, comprenant :

Propionyl-L-carnitine	250 mg
Acétyl-L-carnitine	250 mg
Isovaléryl-L-carnitine	250 mg
L-carnitine	250 mg
Ribose	2 g

EP 1 292 312 B1

(suite)

L-glutamine	100 mg
L-alanine	100 mg
L-arginine	100 mg
L-glycine	100 mg
L-histidine	100 mg
L-isoleucine	100 mg
L-phénylalanine	50 mg
L-thréonine	50 mg
L-sérine	100 mg

12. Complément selon la revendication 8, sous forme de dose unitaire, comprenant :

Propionyl-L-carnitine	250 mg
Acétyl-L-carnitine	250 mg
Isovaléryl-L-carnitine	250 mg
L-carnitine	250 mg
Ribose	1 g
Glucose-1,6-diphosphate	200 mg
Fructose-1,6-diphosphate	200 mg
Galactose-1,6-diphosphate	200 mg
Glycérol-3-phosphate	200 mg
Phosphénylpyruvate	100 mg
Pyrophosphate de thiamine	5 mg
Pyridoxal-5-phosphate	5 mg
Stéarate de magnésium	2 mg

13. Complément selon la revendication 8, sous forme de dose unitaire, comprenant :

Propionyl-L-carnitine	250 mg
Acétyl-L-carnitine	250 mg
Isovaléryl-L-carnitine	250 mg
L-carnitine	250 mg
Ribose	1 g
Vitamine A	1250 U.I.
Vitamine B ₁	0,5 mg
Vitamine B ₆	30 mg
Vitamine C	50 mg
Vitamine E	5 mg
Nicotinamide	25 mg
Vitamine B ₁₂	100 mcg
Vitamine D	100 U.I.
Acide pantothénique	30 mg
Glycinate de magnésium	5 mg
Manganèse	1 mg
L-sélénométhionine	50 mcg
Molybdène	10 mcg
Zinc	1 mg

14. Utilisation d'une composition de combinaison comprenant les ingrédients suivants :

(a) une L-carnitine alcanoylée choisie parmi le groupe comprenant l'isovaléryl-L-carnitine, la propionyl-L-car-

EP 1 292 312 B1

nitine ou leurs sels pharmacologiquement acceptables ou des mélanges de ceux-ci ; et
(b) du ribose ou un de ses dérivés phosphorylés,

pour la fabrication d'un médicament destiné à la prévention et/ou au traitement des états de dysfonctionnements myocardiques ou musculaires squelettiques liés à des états d'anoxie ou d'approvisionnement insuffisant en énergie tels que ceux se produisant dans les maladies coronariennes ou post-infarctus ou pendant une activité physique prolongée et une fatigue musculaire.

5

10

15

20

25

30

35

40

45

50

55

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.